FDA Inspection 1310410 — Labcorp Drug Development

Labcorp Drug Development — FEI 3023178483

The FDA completed an inspection of Labcorp Drug Development on Jan 30, 2026 in Shanghai. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Jan 30, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Shanghai (China)

Additional details

Bioanalytical BA/BE

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.